Group Leader, Cancer Biology Responsibilities: Lead, mentor and develop the professional capabilities of a group of specialists focused on Oncological drug development, interacting with scientists across the Drug Discovery Research organization Successfully drive Oncological projects for the clinic by executing excellent leadership, organizational and scientific skills Integrate new areas of Cancer Biology, such as epigenetics and stem cells Collaborate with Systems Biology and Computational scientists to identify and validate novel targets and pathways relevant to cancer Collaborate with the Assay Development Group to guide the designing and implementation of relevant primary and secondary assays for compound screening Supervise the cancer In Vivo Biology activities, especially in external partnerships; utilize in vivo modeling to establish the link between biological targets and a disease phenotype Establish and leverage on internal and external networks to accelerate drug discovery and development efforts Participate in the creation of a Fully Integrated Pharmaceutical Network (FIPNET) Oversee recruiting and staffing activities Requirements: Possess a minimum of 7 years’ research experience, of which a minimum of 3 years should be in the pharmaceutical or biotechnology industry, specializing in Oncological therapeutics and/ or biotherapeutics Demonstrated ability to provide scientific and administrative leadership across multi-disciplinary project teams on Oncological drug discovery Ability to manage a portfolio of projects and activities Established external scientific network in Cancer Biology Familiarity with using bioinformatics approaches to discover new drugs Proven ability to work collaboratively and effectively across multiple time zones Strong track record in publications Long-term business trip in Singapore

企业介绍:
美国礼来公司（Eli Lilly and Company）是一家全球性的以研发为基础的医药公司，致力于为全人类提供以药物为基础的创新医疗保健方案，使人们生活过得更长久、更健康、更有活力。 礼来是拥有130年历史的世界领先制药公司。礼来于1918年来到中国，将其第一个海外代表处设在上海，从而迈出了全球化的第一步。虽然几经风雨，我们始终不能割舍中国情结，在1993年重新回到中国。重返中国十余年来，礼来迈着坚定的步伐，在中国的改革大潮中稳步前进，已成为业界增长速度最快的制药公司之一。至今，我们在全国拥有一家独资企业：礼来苏州制药有限公司，30家办事机构，员工近1000人，并与中国科研机构联合进行合成化学研究。 礼来在中国的许多医药领域居领先地位，如抗生素、中枢神经、肿瘤、内分泌等。我们的品牌希刻劳、稳可信、百优解、再普乐、欣百达、择思达、健择、力比泰、易维特、希爱力、人工胰岛素优泌林及其最佳伴侣优伴等已被公认为创新的药物。它们挽救了病人生命、提高了大众的生活品质，同时也为患者、保健提供者和支付方创造了价值，降低了疾病治疗的成本。